Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(60.0%)
Phase 1
2(40.0%)
5Total
Early Phase 1(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07483346Phase 1Not Yet Recruiting

IASO-782 in Systemic Lupus Erythematosus

Role: lead

NCT06534021Phase 1Not Yet Recruiting

IASO-782 in Autoimmune Hematological Diseases

Role: lead

NCT05141253Early Phase 1Recruiting

Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

Role: collaborator

NCT05166070Early Phase 1Recruiting

An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

Role: collaborator

NCT04767308Early Phase 1Unknown

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Role: collaborator

All 5 trials loaded